Global Myelodysplastic Syndrome Therapeutics Market 2018-2022

Global Myelodysplastic Syndrome Therapeutics Industry Overview

Our market research analysts have identified the increasing need for cost-effective stem cell therapies as one of the key factors impelling the market’s growth in the forthcoming years. In this treatment, a patient receives high-dose chemotherapy or total body irradiation, followed by infusion of new blood-forming stem cells. The high costs associated with the various types of SCT encourages the manufacturers to curb these costs by conducting research for developing grafts based on stem cells. For instance, Gamida Cell is promoting the development of a standalone graft derived from a single umbilical cord blood unit, which can be expanded in culture and enriched with stem and progenitor cells.

“NiCord is aimed as a cure for patients who do not get a fully matched donor for bone marrow transplantation. It could be used instead of transplanting un-manipulated cord blood in patients with hematological malignancies. NiCord could be a cost-effective option compared with conventional transplantation as it would avoid the need to search for a donor.”, says a senior research analyst at Technavio for the infectious and rare diseases industry.

Want to know what goes into a Technavio report? Get a FREE sample to see selected illustrations and analysis straight from this report.

Companies covered

The myelodysplastic syndrome therapeutics market is quite concentrated owing to the presence of very few manufacturers offering products to the increasing population suffering from MDS. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this myelodysplastic syndrome therapeutics analysis report will aid clients in identifying new growth avenues and design innovative strategies to achieve product differentiation and increased geographic presence.

The report offers a complete analysis of few companies including:

• Celgene
• Otsuka
• Novartis

Myelodysplastic syndrome therapeutics market growth based on geographic regions

• Americas
• APAC
• EMEA

With a complete study of the growth opportunities for the companies across regions such as the Americas, APAC, and EMEA, our industry research analysts have estimated that countries in the Americas were the leading revenue contributors for the MDS therapeutics market during the predicted period.

Get more value with Technavio’s INSIGHTS subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Try the demo

Key highlights of the global myelodysplastic syndrome therapeutics market for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the myelodysplastic syndrome therapeutics market during the next five years
• Precise estimation of the global myelodysplastic syndrome therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• Growth of the myelodysplastic syndrome therapeutics industry across various geographies such as the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive information about factors that will challenge the growth of myelodysplastic syndrome therapeutics companies

This market research report analyzes the market outlook and provides a list of key trends, drivers, and challenges that are anticipated to impact the global myelodysplastic syndrome therapeutics market and its stakeholders over the forecast years.

Market analysts at Technavio have also considered how the performance of other related markets in the vertical will impact the size of this market till 2022. One of the markets most likely to influence the growth of the myelodysplastic syndrome therapeutics market over the coming years is the radiation oncology market.

Technavio also provides customized reports based on the specific requirements of clients.